Treatments for symptomatic urinary tract infections during pregnancy.
BACKGROUND
Urinary tract infections, including pyelonephritis, are serious complications that may lead to significant maternal and neonatal morbidity and mortality. There is a large number of drugs, and combination of them, available to treat urinary tract infections, most of them tested in non-pregnant women. Attempts to define the optimal antibiotic regimen for pregnancy have, therefore, been problematic.


OBJECTIVE
The objective of this review was to determine, from the best available evidence from randomised controlled trials, which agent is the most effective for the treatment of symptomatic urinary tract infections during pregnancy in terms of cure rates, recurrent infection, incidence of preterm delivery and premature rupture of membranes, admission to neonatal intensive care unit, need for change of antibiotic, and incidence of prolonged pyrexia.


METHODS
We searched the Cochrane Pregnancy and Childbirth Group Trials Register (November 2009) and reference lists of articles.


METHODS
We considered all trials where the intention was to allocate participants randomly to one of at least two alternative treatments for any symptomatic urinary tract infection.


METHODS
Both review authors assessed trial quality and extracted data.


RESULTS
We included 10 studies, recruiting a total of 1125 pregnant women. In most of the comparisons there were no significant differences between the treatments under study with regard to cure rates, recurrent infection, incidence of preterm delivery, admission to neonatal intensive care unit, need for change of antibiotic and incidence of prolonged pyrexia. When cefuroxime and cephradine were compared, there were better cure rates (29/49 versus 41/52) and fewer recurrences (20/49 versus 11/52) in the cefuroxime group. There was only one other statistically significant difference when comparing outpatient versus inpatient treatment. Gestational age at birth was greater in women from the outpatient group (38.86 versus 37.21), while birthweight was on average greater in the inpatient group (3120 versus 2659).


CONCLUSIONS
Although antibiotic treatment is effective for the cure of urinary tract infections, there are insufficient data to recommend any specific drug regimen for treatment of symptomatic urinary tract infections during pregnancy. All the antibiotics studied were shown to be very effective in decreasing the incidence of the different outcomes. Complications were very rare. All included trials had very small sample sizes to reliably detect important differences between treatments. Future studies should evaluate the most promising antibiotics, in terms of class, timing, dose, acceptability, maternal and neonatal outcomes and costs.
Departamento de Salud Reproductiva, Instituto Nacional de Endocrinologia (INEN), Zapata y D, Vedado, Habana, Cuba, 10 400.
Juan C
JC
Vazquez
Edgardo
E
Abalos
D000892:Anti-Infective Agents, Urinary / Q000627:therapeutic use*; D001724:Birth Weight; D002444:Cefuroxime / Q000627:therapeutic use; D002515:Cephradine / Q000627:therapeutic use; D005260:Female; D005865:Gestational Age; D006801:Humans; D017063:Outcome Assessment, Health Care; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic; D014552:Urinary Tract Infections / Q000188:drug therapy*
D000892:Anti-Infective Agents, Urinary; D002515:Cephradine; D002444:Cefuroxime
Clin Perinatol. 1997 Mar;24(1):43-57
9099501
BMJ. 1996 Jul 6;313(7048):36-9
8664772
Med J Aust. 1972 Feb 5;1(6):261-3
4552260
Urol Int. 1987;42(5):338-41
3324441
Antimicrob Agents Chemother. 1985 Apr;27(4):508-10
4004191
Br J Obstet Gynaecol. 1985 May;92(5):498-505
3888250
Rev Med Chil. 2000 Jul;128(7):749-57
11050836
Br Med J. 1972 Jun 17;2(5815):673-6
4555654
Clin Exp Obstet Gynecol. 2007;34(2):85-7
17629158
Scand J Infect Dis. 1979;11(4):275-9
231299
Int J Antimicrob Agents. 2001 Apr;17(4):279-82
11295408
Jpn J Antibiot. 1976 Feb;29(2):167-77
772246
Obstet Gynecol. 1990 Jul;76(1):28-32
2193265
Baillieres Clin Obstet Gynaecol. 1994 Jun;8(2):353-73
7924012
J Natl Med Assoc. 1992 Jan;84(1):73-5
1602504
Chemotherapy. 1990;36 Suppl 1:50-2
2085991
Med J Aust. 1969 Sep 20;2(12):596-600
5388374
Drugs. 1987;34 Suppl 1:100-6
3501750
Eur Urol. 1987;13 Suppl 1:108-13
3552694
Lancet. 1965 Feb 20;1(7382):395-9
14238090
Cochrane Database Syst Rev. 2003;(4):CD002256
14583949
Rev Infect Dis. 1990 May-Jun;12(3):458-67
2193352
N Engl J Med. 1971 Oct 7;285(15):820-4
4936826
Ginecol Obstet Mex. 1989 Mar;57:57-63
2487304
Obstet Gynecol. 1998 Aug;92(2):249-53
9699761
Ann Pharmacother. 1998 Feb;32(2):215-9
9496408
Drugs. 1997 Apr;53(4):637-56
9098664
Infect Dis Obstet Gynecol. 1996;4(5):294-7
18476110
Cochrane Database Syst Rev. 2019 Nov 25;2019(11):
31765489
Obstet Gynecol. 1990 Nov;76(5 Pt 1):891-2
2216244
Med J Aust. 1973 Jun 30;1(2):Suppl:44-8
4580586
Obstet Gynecol. 1995 Oct;86(4 Pt 1):560-4
7675380
Br J Urol. 1975 Jun;47(3):335-41
1095107
Am J Obstet Gynecol. 1995 Jan;172(1 Pt 1):129-33
7847521
Obstet Gynecol. 1999 Nov;94(5 Pt 1):683-8
10546710
J Reprod Med. 1987 Dec;32(12):895-900
3430498
Clin Obstet Gynecol. 1988 Sep;31(3):553-84
3066544
Obstet Gynecol. 1996 Mar;87(3):479-80
8598983